STAT+: Schizophrenia drug AbbVie picked up in $9 billion acquisition fails in key trials
STAT
NOVEMBER 11, 2024
AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent $9 billion acquisition of Cerevel Therapeutics. In Phase 2 studies, patients on different doses of the drug, called emraclidine, did not experience significant improvements on a test called the Positive and Negative Syndrome Scale (PANSS) compared with the placebo group.
Let's personalize your content